The results of the TATTON trial showed that the combination of savolitinib and osimertinib can prolong the survival of patients with advanced EGFR-TKI-resistant NSCLC and high-level acquired MET amplification. The gene discussed is MET; the disease is non-small cell lung carcinoma.